Karyopharm Signs Merger Agreement with Ayrmid

Karyopharm Therapeutics' Chapter 11 filing introduces a court-supervised transition that places GMP site obligations, FDA post-market commitments, and supply continuity for selinexor (Xpovio) under immediate scrutiny for QA directors and regulatory affairs leads managing hematology supply chains. The Newton, Mass.-based company filed voluntary petitions in the U.S. Bankruptcy Court for the Southern District of Texas on November 2, 2026, alongside a Restructuring Support Agreement naming Ayrmid Ltd. as lead bidder in a court-supervised sale process.

The transaction is structured as a merger between Ayrmid and a reorganized Karyopharm, with closing targeted for Q1 2027, subject to Chapter 11 plan approval. Competing bids remain permissible under the court-approved bidding procedures Karyopharm will seek, meaning the ultimate acquirer of manufacturing and regulatory assets is not yet confirmed.

To bridge operations through the process, Karyopharm has secured up to $55 million in debtor-in-possession (DIP) financing from existing secured lenders, pending court approval. The company states that ordinary course operations, including commercial supply of selinexor for multiple myeloma and myelofibrosis indications, are expected to continue uninterrupted. For plant heads and supply assurance teams, that assertion warrants independent verification against existing supply agreements and any FDA commitments tied to approved 21 CFR Part 211 site registrations.

Ayrmid, whose chairman and CEO Dr. Joe Wiley cited complementary portfolios in hematology, has not disclosed its own manufacturing infrastructure or quality system alignment with Karyopharm's existing GMP framework. Any post-merger site transfer or contract manufacturing organisation change would trigger comparability and validation obligations under ICH Q10 and relevant post-approval supplement requirements, timelines that rarely compress to fit a Q1 close.

Regulatory affairs leads should also note that Chapter 11 restructurings do not suspend FDA obligations: NDA holder responsibilities, REMS program administration for selinexor, and post-market surveillance commitments remain with the legal entity until a court-confirmed plan transfers them to a successor. Clarity on that transfer mechanism will be a critical checkpoint as the Chapter 11 plan moves toward confirmation.

The confirmed DIP financing amount, $55 million, and the Q1 2027 target close date are the two measurable markers against which operational and regulatory continuity can be tracked through the court process.

Source: Karyopharm Therapeutics Investor Relations via PRNewswire, November 2, 2026.